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Background: The oxidative modiﬁcations of bioactive macromolecules have important roles in carcino-
genesis. Of particular interest are lipid peroxidation products, which are involved in the activation of Nrf2
and endocannabinoids that affect cancer progression.
Methods: In lung cancer tissues (squamous cell lung carcinoma - SCC and adenocarcinoma - AC), the
glutathione peroxidase and catalase activity and glutathione level, together with the expression of Nrf2
and its activators/inhibitors were estimated. The oxidative modiﬁcations of DNA (8-hydroxy-2′-deox-
yguanosine and N7-methylguanine), endocannabinoids (anandamide and 2- arachidonylglyceriol), their
receptors (CB1/2, TRV1, GPR55), phospholipid fatty acids (arachidonic, linoleic and docosahexaenoic),
and reactive aldehydes (4-hydroxynonenal, 4-oxononenal and malondialdehyde) were determined.
Results: Tumour tissues showed lower antioxidant capacity than healthy tissues, which was accom-
panied by lower levels of fatty acids and higher levels of reactive aldehydes. Disturbances in antioxidant
capacity and enhanced DNA oxidative modiﬁcations were observed in 88% of AC patients and 81% of SCC
patients. The 4-hydroxynonenal-Histidine adducts were detected in the necrotic and stromal cells in all
tumours. These ﬁndings were associated with the enhanced Nrf2 activity, especially in AC. The strong
difference between the cancer subtypes was evident in the levels of endocannabinoids, with an increase
in 89% of SCC and a decrease in 85% of AC patients being observed. Additionally, the increase in the
expression of CB1/2 receptors was observed only in 82% of AC, while the expression of VR1 and GPR55
was enhanced in 79% of SCC and 82% of AC patients.
Conclusions: This study shows signiﬁcant differences in the redox status, Nrf2 pathway and en-
docannabinoid system between SCC and AC tissues. Understanding the relation between the various lipid
mediators and antioxidants in different lung cancer subtypes may be beginning for further research on
the effective anticancer therapy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung malignancies are the leading cause of death in both men
and women. More than 85% of lung cancers are non-small cell lung
cancers (NSCLC), including the two most common histological
subtypes of NSCLC: squamous cell lung carcinoma (SCC – ap-
proximately 30% of all lung cancers), and adenocarcinoma (AC –
approximately 40% of all lung cancers, occurring more often in
women than in men and in younger people than other subtypes of
lung cancers) [1].
Cancer development is characterised by redox imbalance with
a shift towards oxidative conditions. As a consequence, the oxi-
dative modiﬁcations of cellular components, including phospho-
lipids, DNA and proteins, are accumulated in tumour cells causing
additional disturbances in their metabolism [2]. Several studies
have shown that the lipid peroxidation products such as reactive
aldehydes are involved in the intracellular signalling pathways and
activation of transcription factors in cancer cells [3].
Nrf2 (nuclear factor erythroid-2 related factor 2) is one of the
major transcription factors that are constitutively activated in
many cancer cells [4]. Nrf2 is a cap 'n' collar basic leucine zipper
transcription factor, which regulates the expression of antioxidant
enzymes and several anti-apoptotic proteins, which confer cyto-
protection against oxidative stress and apoptosis [5]. Nrf2 activates
the transcription of target genes through binding to the anti-
oxidant response element (ARE) found in those gene promoters.
The genes regulated by Nrf2 encode antioxidants, xenobiotic me-
tabolism enzymes and several ATP-dependent drug efﬂux pumps
[6]. Therefore, the constitutive activation of Nrf2 in cancer pro-
motes tumourigenicity and contributes to chemoresistance.
However, the xenobiotic metabolism enzymes in conjunction with
drug efﬂux proteins detoxify cancer drugs, whereas antioxidants
provide cytoprotection by attenuating drug-induced oxidative
stress and apoptosis [7]. Therefore, chemotherapy for advanced,
inoperable NSCLC is generally palliative.
Nrf2 activity is regulated by its cytoplasmic anchor – Keap1
(Kelch-like ECHassociated protein 1) that forms a complex with
the transcription factor. Several studies have shown that the
constitutive activation of Nrf2 in lung cancer is strongly connected
with mutations in the Keap1 gene [8,9]. In physiological condi-
tions, Keap1 constitutively suppresses Nrf2 activity; however,
electrophilic compounds hamper the Keap1-mediated proteaso-
mal degradation of Nrf2, leading to the transcriptional induction of
target genes that ensure cell survival [10]. It was found that in the
case of lung cancer, mutation of a glycine to cysteine in its DGR
domain reduces the afﬁnity of Keap1 for Nrf2 [11]. It was found
that Keap1 is a cysteine-rich protein that is highly susceptible to
electrophilic molecules, such as reactive oxygen species (ROS) or
reactive aldehydes, which are the products of lipid peroxidation
(e.g., 4-HNE). Their interactions with Keap1 lead to changes in its
conﬁrmation and thereby to Nrf2 activation. Complexes of 4-HNE-
Keap1 were detected in NSCLC [12]. It was also observed that
4-HNE occurs at a higher level in human lung cancer cells and acts
as a signalling molecule promoting tumour cell viability [13].
Other lipid mediators, such as endocannabinoids like anandamide
(AEA) and 2-arachidonylglyceriol (2-AG), are also known to affect
the progression of cancer development [14], but the exact me-
chanism of their action is unknown. Endocannabinoids belong to
the endocannabinoid system, which is involved in the reaction of
cancer cells to the generation of higher levels of reactive oxygen
species [15]. Moreover, natural and synthetic cannabinoids as well
as their receptors, CB1, CB2, TRV1, and GPR55, and enzymes in-
volved in the endocannabinoid metabolism have been reported to
affect cancer growth at more than one step in several subtypes of
malignancies [16]. Accordingly, previous studies identiﬁed the
anti-tumourigenic activities of cannabinoids, such as inhibition oftumour cell proliferation [17] and angiogenesis [18], as well as
induction of apoptosis and autophagy [19]. Cannabinoids and en-
docannabinoid-related compounds were able to affect lung cancer
cell proliferation, induce apoptosis, and inhibit migration and in-
vasiveness [20]. In NSCLC, cannabinoids inhibit cancer cell inva-
sion via increasing the expression of tissue inhibitor of matrix
metalloproteinases-1 (TIMP-1) [21]. It was shown that the en-
docannabinoid system components protect cancer cells against the
higher levels of reactive oxygen species [15] and affect Nrf2 ac-
tivity [22].
Therefore, the aim of this study was to evaluate the relationship
between the lipid mediators and activity of the transcription factor
and compare these relationships in the two main subtypes of
human NSCLC: squamous cell lung and adenocarcinoma. Finding
and understanding the differences in the mechanisms of Nrf2
activation in these cancers may be applied in anticancer therapies.2. Material and methods
Surgically resected non-small cell lung cancer [NSCLC] and
adjacent normal tissue specimens were collected from a group of
28 female and 44 men with a mean age of 62 (4677) years. All
patients underwent pulmonary resection for primary NSCLC in the
Department of Thoracic Surgery of the Medical University of Bia-
lystok, Poland and the University of Zagreb School of Medicine,
Clinical Hospital Centre Zagreb, Division of Pathology, Croatia.
Thirty eight samples from patients with pulmonary squamous cell
carcinoma (SCC) (12 female and 26 men with mean age of 62
((4677)years)) and 34 samples from patients with adenocarci-
noma (AC) (16 female and 18 men with mean age of 60 ((5072)
years)) were collected.
The inclusion criteria for the current study were the following:
original diagnosis of lung AC or SCC based on the histologic evi-
dence of glandular differentiation or squamous differentiation,
respectively; completely resected tumour (free resection margins);
stage I or stage II NSCLC; a minimum of three-year follow-up in-
cluding monitoring for events of cancer recurrence and lung
cancer–related death; availability of representative fresh-frozen
tumour specimens (the material containing at least 50% tumour
cells for DNA extraction); and no adjuvant chemotherapy. This
study was approved by the Institutional Ethical Committee of the
Medical University of Bialystok as well as the University of Zagreb
School of Medicine and informed consent was obtained from each
patient. The exclusion criteria were as follows: lack of written
consent; recent treatment with certain medications, including
nonsteroidal anti-inﬂammatory drugs, steroids, and oral contra-
ceptives; alcohol abuse; and heavy smokers.
A piece of each collected tissue was homogenised under stan-
dardized conditions; 10% homogenates were centrifuged at
10,000 g for 15 min at 4 °C, and the supernatants were stored at
–80 °C and used for the estimation of biochemical parameters.
2.1. Antioxidant parameters
2.1.1. Determination of glutathione peroxidase activity
Glutathione peroxidase (GSH-Px – EC.1.11.1.6) activity was as-
sessed spectrophotometrically using the method of Paglia and
Valentine [23]. GSH-Px activity was assayed by measuring the
conversion of NADPH to NADP. One unit of GSH-Px activity was
deﬁned as the amount of enzyme catalysing the oxidation of 1
μmol NADPH min1 at 25 °C and pH 7.4. Enzyme speciﬁc activity
was expressed in units per mg of protein.
2.1.2. Determination of catalase activity
Catalase (CAT – EC.1.11.1.9) activity was determined by
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240 nm [24]. One unit of CAT was deﬁned as the amount of the
enzyme required to catalyse the decomposition of 1 μmol hydro-
gen peroxide to water and oxygen for 1 min. Enzyme speciﬁc ac-
tivity was expressed in units per mg of protein.
2.1.3. Determination of glutathione level
Glutathione and its oxidised form were quantiﬁed using ca-
pillary electrophoresis (CE).method of Maeso [25]. Samples were
soniﬁcated in the Eppendorf tubes with 2 ml of a mixture con-
taining AcN/H2O (62.5:37.5, v/v) and centrifuged at 29,620 g for
10 min. The supernatant was immediately measured by CE. The
separation was performed on a capillary with 47 cm total length
(40 cm effective length) and 50 m i.d. and was operated at 27 kV
with UV detection at 200710 nm. The GSH concentration was
determined using a calibration curve range: 1120 nmol/L (r2-
0.9985).
2.2. Nrf2/ARE pathway
Western blot analysis of cell protein was performed according
to Eissa and Seada [26]. Whole homogenate were mixed with
Laemmle buffer containing 5% 2-mercaptoethanol, heated at 95 °C
for 10 min, and separated by 10% Tris-Glycine SDS-PAGE. Sepa-
rated proteins were electrophoretically transferred into ni-
trocellulose membrane. The blotted membrane was blocked with
5% skim milk in TBS-T buffer (5% Tween 20) for 1 h. Primary
monoclonal antibodies were raised against Nrf2, phospho-Nrf2
(pSer40), Nrf3, p62, Keap1, ERK1/2, phospho-ERK1/2 (pThr202/
pTyr204), cJun, phosphor-cJun (pSer63), NFκB (p52), (Santa Cruse
Biotechnology, Santa Cruz, CA, USA), Nrf1, Bach1, HO-1 (Sigma-
Aldrich, St. Louis, MO, USA), p21, and KAP1 (Abcam Inc., Cam-
bridge, MA, USA) were used at a concentration of 1:1000. Protein
bands were visualised using the BCIP/NBT Liquid substrate system
(Sigma-Aldrich, St. Louis, MO, USA) and were quantitated using the
Versa Doc System and Quantity One software (Bio-Rad Labora-
tories Inc., CA). Total protein content in homogenate was measured
using a Bradford assay [27].
2.3. DNA modiﬁcations
2.3.1. Determination of 8-hydroxy-2′-deoxyguanosine level
8-hydroxy-2′-deoxyguanosine (8-OHdG) was assayed by mod-
iﬁed LC-MS method of Dizdaroglu et al. [28]. DNA isolation was
performed using Sigma's GenElute Mammalian Genomic DNA
Miniprep kit. DNA concentration in the preparations was de-
termined spectrophotometrically. DNA samples were stored at
70 oC until hydrolysis. DNA hydrolysis to nucleosides: DNA
samples (200 μl) were mixed with 100 μl of 40 mM sodium acet-
ate, 0.1 mM ZnCl2, pH 5.1 and 20 μl nuclease P1 solution (20 μg
protein). Samples were incubated for one hour at 37 oC. Thereafter
30 μl of 1 M Tris–HCl, pH 7.4 and 5 μl of alkaline phosphatase so-
lution containing 1.5 units of the enzyme were added to each
sample following 1 h incubation at 37 °C. All DNA hydrolysates
were ultraﬁltered using Ultrafree-MC ﬁlter units (cut off 5000 Da).
8-OHdG in hydrolysates was determined using Agilent 1290 LC
system and Agilent 6460 triple quadrupole mass spectrometer
equipped with electrospray ionization ESI source. Solvent A [0.1%
formic acid in water] and solvent B [0.1% formic acid in methanol]
were used in gradient mode to achieve the desired sample se-
paration. The ﬂow rate was 0.4 ml/min. The following gradient was
run: 0 min, 5% solvent B; 0–8.0 min, 50% solvent B; 8.0–8.1 min,
100% solvent B; 8.01–12.0 min, 100% solvent B; 12.0–13.0 min, 5%
solvent B. LC–MS/MS analysis was performed using a Agilent 1290
HPLC system interfaced with a Agilent 6560 triple quadrupole
mass spectrometer with electrospray ion source (ESI). The sampleswere analysed in the positive ion multiple reaction monitoring
(MRM) mode and the transitions of the precursors to the product
ions were as follows: m/z 284.1-168 (quantiﬁer ion) and 284.1-
69 (qualiﬁer ion). The calibration curve for detection of 8-OHdG
was linear in the study range of 50–500 fmol. The LOQ and LOD
was 3.0 and 1.5 residues/106 dG. The amount of 8-OHdG was
calculated as the number per 105 deoxyguanosine.
2.3.2. Determination of N7-methylguanine level
N7-methylguanine (N7-MeG) was assayed by modiﬁed LC-MS
method of Chao et al. [29]. The DNA solutions were subjected to
neutral thermal hydrolysis at 100°C for 30 min. The DNA was
precipitated and the supernatant was dried under vacuum and
redissolved in 200 ml of 96% (v/v) acetonitrile with 0.1% formic
acid for HPLC analysis. LC–MS/MS analysis was performed using a
Agilent 1290 HPLC system interfaced with a Agilent 6560 triple
quadrupole mass spectrometer with electrospray ion source (ESI).
The samples were analysed in the positive ion multiple reaction
monitoring (MRM) mode and the transitions of the precursors to
the product ions were as follows: m/z 166-149 (quantiﬁer ion)
and 166-124 (qualiﬁer ion) for N7-MeG, m/z 171-153. Linear
calibration curve covering the range 1– 10,000 pg was obtained by
serial dilution of calibration solution. The LOQ was determined to
be 0.06, ng/ml on-column. The LOD, deﬁned as the lowest con-
centration that gave a signal-to noise ratio of at least 3, was found
to be 0.02 ng/ml on-column (6.1 fmol, which correspond to
1.6 adducts per 106 unmodiﬁed bases).
2.4. PUFAs and lipid peroxidation products
2.4.1. Determination of PUFAs level
Arachidonic (AA), linoleic (LA) and docosahexaenoic (DHA)
acids were determined by gas chromatography [30]. Lipid com-
ponents were isolated from cell lysates by extraction using
chloroform/methanol mixture (2:1, v/v). Using TLC, total phos-
pholipids were separated with the mobile phase heptane - diiso-
propyl ether – acetic acid (60:40:3, v/v/v). All lipid fractions were
transmethylated to fatty acid methyl esters (FAMEs) with boron
triﬂuoride in methanol reagent under nitrogen atmosphere with-
out previous separation from the layer. The FAMEs were analysed
by gas chromatography with a ﬂame ionisation detector. Separa-
tion of FAME was carried out on capillary column coated with
Varian CP-Sil88 stationary phase.
2.4.2. Determination of lipid modiﬁcations
Lipid peroxidation was estimated by measuring the level of
4-hydroxynonenal (4- HNE), 4-oxononenal (4-ONE) and mal-
ondialdelhyde (MDA). Aldehydes were measured by GC/MSMS, as
the O-PFB-oxime-TMS derivatives, using modiﬁed method of Luo
[31]. Benzaldehyde-D6 as an internal standard was added to the
cell lysates and aldehydes were derivatized by the addition of O-
(2,3,4,5,6-pentaﬂuoro-benzyl) hydroxyamine hydrochloride
(0.05 M in PIPES buffer, 200 μl) and incubating for 60 min at room
temperature. After incubation, samples were deproteinized by the
addition of 1 ml of methanol and O-PFBoxime aldehyde deriva-
tives were extracted by the addition of 2 ml of hexane. The top
hexane layer was transferred into borosilicate tubes, and evapo-
rated under a stream of argon gas followed by the addition of N,O-
bis(trimethylsilyl)triﬂuoroacetamide in 1% trimethylchlorosilane.
A 1 μl aliquot was injected on the column. Derivatized aldehydes
were analysed using a 7890 A GC – 7000 quadrupole MS/MS
(Agilent Technologies, Palo Alto, CA) equipped with a HP-5 ms
capillary column (0.25 mm internal diameter, 0.25 mm ﬁlm thick-
ness, 30 m length). Derivatized aldehydes were detected in se-
lected ion monitoring (SIM) mode. The ions used were: m/z 332,0
and 181,0 for 4-ONE-PFB, m/z 333.0 and 181.0 for 4-HNE-PFB-TMS,
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2.4.3. Determination of 4-HNE-protein adducts
The 4-HNE-protein adduct ELISA is a method for the detection
of 4-HNE bound to proteins, which is considered as the most likely
form of 4-HNE occurrence in living systems. This ELISA method
was utilised from protocol described by Weber et al. [32] that was
adapted from original method by Borovic et al. [33]. 4-HNE-BSA
standards in the range from 0 to 250 pmol/mg were used, with
ﬁnal concentration of BSA being 10 mg/ml. Accordingly, all plasma
samples were diluted in PBS to protein concentration of 10 mg/ml.
Protein concentration of standards and plasma was determined by
the BioRad assay according to Bradford [37]. Prepared standards/
plasma samples were diluted 10-fold in 50 mM carbonate binding
buffer (pH 9.6; 15 mM sodium carbonate, 35 mM sodium bi-
carbonate) into ELISA plate wells (Nunc Immuno Maxisorp, Ther-
mo Scientiﬁc) for duplicate analysis in 100 μl volumes per well.
Proteins were adsorbed for 5 h at 4°C. Plates were washed once
with PBS and incubated with blocking solution (5% fat free dry
milk in carbonate binding buffer) for 2.5 h at room temperature
(RT) followed by one washing step (0.1% Tween 20 in PBS), all done
in 300 μl per well volumes. 100 μl of primary antibody solution in
1% BSA in PBS was incubated at 4°C overnight (genuine anti
4-HNE-His murine monoclonal antibody, clone 4- HNE 1g4; 1:100,
v/v). After washing the wells seven times (0,1% Tween 20 in PBS),
the plates were incubated for 30 min with peroxidase blocking
solution (3% H2O2, 3% fat free dry milk in PBS) at RT, followed by
seven times washing step. 100 μl of the goat anti-mouse secondary
antibody solution in 1% BSA in PBS (1:100; Dako, Carpinteria, CA,
USA) was incubated for 1 h at RT, followed again by a seven time
washing step. 100 μl of chromogen substrate solution (0.1 mg/ml
TMB, 0.012% H2O2) in citric buffer (26.5 mM citric acid anhydrous,
51 mM sodium hydrogen phosphate dihydrate) was incubated for
40 min at RT. The reaction was stopped by adding 50 μl of 2 M
sulphuric acid. Absorption was read at 450 nm with the reference
ﬁlter set to 620 nm. Amounts of 4-HNE–protein adducts measured
by the ELISA were expressed as pmol 4-HNE per mg of proteins.
4-HNE-His immunohistochemistry of the tissue specimens was
done using the same monoclonal antibodies, as was done for the
4-HNE-ELISA. For the immunohistochemical detection of the HNE-
adducts the immunoperoxidase technique was used, with sec-
ondary rabbit-anti-mouse antibodies (Dako, Glostrup, Denmark),
applied on 5 mm sections of the formalin-ﬁxed parafﬁn embedded
sections of the tumours, as described before [34].
2.5. Endocannabinoid system
2.5.1. Determination of endocannabinoids level
Anandamide (AEA) and 2-arachidonylglyceriol (2-AG) were
quantiﬁed using modiﬁed ultrahigh performance liquid chroma-
tography-tandem mass spectrometry (UPLC-MS/MS) by Lam
method [35]. Octadeuterated endocannabinoids: AEA-d8 and
2-AG-d8 as internal standards were added into the homogenate
and all cannabinoids were isolated using a solid phase extraction
(SPE). UPLC–MS/MS analysis was performed using an Agilent 1290
UPLC system with a Zorbax Extend C18 column
(2.1 mm150 mm, 1.8 mm, Agilent, Santa Clara, CA, USA) and
interfaced with an Agilent 6460 triple quadrupole mass spectro-
meter with electrospray ionisation source (ESI). The samples were
analysed in positive-ion mode using multiple reaction monitoring
(MRM). Transition of the precursor to the product ion for AEA was:
m/z 348.3-62.1, and for 2-AG: m/z 379.3-287.2. The linear dy-
namic range was 0.2–200 ng/g for AEA and 0.8–100 μg/g for 2-AG.
The LOQ value was 0.2 ng/g for AEA, and 0.8 μg/g for 2-AG, while
the LOD values were 0.02 ng/g and 0.08 μg/g, respectively.2.5.2. Determination of MAGL activity
Monoacylglycerol lipase (MAGL - EC 3.1.1.23) activity was
measured in the homogenate prepared in 20 mM Tris, 320 mM
sucrose, 1 mM EDTA, pH 8.0. Supernatant was obtained from the
soluble fraction after spinning the homogenate at 1000 g for
15 min. Reaction mixture containing liver supernatants, 10 mM
Tris, 1 mM EDTA pH 7.2 was preincubated at 4 °C for 15 min. After
addition of arachidonoyl-1-thio-glycerol (A-1-TG) mixture was
incubated at 37 °C for 5 min and after cooling to room temperature
1 mM DTNB was added. After 3 min hydrolysis the absorbance at
412 nm was measured. Enzyme speciﬁc activity was expressed in
nmoles of TNB releasing during 1 min per mg of protein [36].
2.5.3. Determination of FAAH activity
Fatty acid amide hydrolase (FAAH - EC 3.5.1.99) activity was
measured in the homogenate prepared in 20 mM Tris, containing
10% glycerol, 150 mM NaCl, and 1% Triton X-100, pH 7.8 at 4 °C.
After centrifugation (1000 g), 200 μl of the supernatant was ad-
ded to 1750 μl of reaction buffer (125 mM Tris, pH 9.0, and 1 mM
EDTA) and 17 μM FAAH substrate decanoyl m-nitroaniline (m-NA)
(Cayman Chemical Company, Ann Arbor, MI, USA) and absorbance
was measured at 410 nm [37]. Results were normalised to protein
content.
2.5.4. Determination of endocannabinoid receptors expression
Western blot analysis of cell protein was performed according
to Eissa and Seada [26]. Membrane fractions were mixed with
Laemmle buffer containing 5% 2-mercaptoethanol, heated at 95 °C
for 10 min, and separated by 10% Tris-Glycine SDS-PAGE. Sepa-
rated proteins were electrophoretically transferred into ni-
trocellulose membrane. The blotted membrane was blocked with
5% skim milk in TBS-T buffer (5% Tween 20) for 1 h. Primary an-
tibodies were raised against CB1, CB2 (Santa Cruse Biotechnology,
Santa Cruz, CA, USA), VR1 (Abcam Inc., Cambridge, MA, USA) and
GPR55 (Sigma-Aldrich, St. Louis, MO, USA) were used at a con-
centration of 1:1000. Protein bands were visualised using the
BCIP/NBT Liquid substrate system (Sigma-Aldrich, St. Louis, MO,
USA) and were quantitated using the Versa Doc System and
Quantity One software (Bio-Rad Laboratories Inc., CA).3. Statistical analysis
Statistical analysis was performed using StataIC 13.0. Data ob-
tained in the current study are expressed as mean and 7SD. Be-
cause the tissue samples were paired (tumour-free and tumour
tissues from the same individual) the comparison of tumour-free
and tumour tissues between different tumour subtypes was car-
ried out using an ANOVA. The subgroup analyses of the paired
samples in terms of antioxidant expressions were done by paired t
test. P value o0.05 was considered statistically signiﬁcant.4. Results
4.1. Antioxidant capacity
Obtained results demonstrate varying degrees of redox dis-
orders depending on the lung cancer subtype. In the case of GSH-
Px activity, a 4- and 5-fold decrease compared with control tissue
was observed in SCC and AC, respectively. A similar dependence
was also recorded for CAT activity, where a 30% and 60% decrease
was observed in SCC and AC, respectively (Table 1). On the other
hand, GSH level was diminished to approximately 60% in both
subtypes of lung cancer (Table 1).
Table 1
The activity/level of antioxidant enzymes (GSH-Px and CAT) and nonenzymatic
antioxidant (GSH) in the lung cancer tissue [SCC, n¼38 and AC, n¼34] and lung
tissue.
Analysed
parameter
SCC n¼38 AC n¼34
Lung tissue Cancer tissue Lung tissue Cancer tissue
GSH-Px mU/
mg protein
81.173.8 21.271.2a 69.375.1 12.470.8a,b
CAT U/mg
protein
2.1570.13 1.4570.07a 1.8170.11 0.7170.03a,b
GSH [nmoles/
g tissue ]
1.3770.10 0.8270.07a 1.2970.07 0.8070.04a
GSSG [nmol/g
tissues]
0.03870.002 0.06370.007a 0.04470.006 0.05370.009b
GSH/GSSG 36.0570.12 13.070.3a 29.371.4 15.471.9a
a Statistically signiﬁcant differences vs. control group, po0.05.
b Statistically signiﬁcant differences vs. SCC group, po0.05.
Table 2
The level of DNA modiﬁcations [8-OHdG and N7-MeG] in the lung cancer tissue
[SCC, n¼38 and AC, n¼34] and lung tissue.
Analysed
parameter
SCC n¼38 AC n¼34
Lung tissue Cancer tissue Lung tissue Cancer tissue
8-OHdG/105dG 1.9970.70 4.5970.62a 2.3770.82 9.4172.38a,b
N7-MetG (mmoles/
mol G)
15.0172.22 20.9171.06a 13.5471.66 32.7472.81a,b
a Statistically signiﬁcant differences vs. control group, po0.05.
b Statistically signiﬁcant differences vs. SCC group, po0.05.
Table 3
The level of phospholipid fatty acids [ph-LA, ph-AA, and ph-DHA], lipid peroxida-
tion products [4-HNE, MDA, 4-ONE], and 4-HNE – protein adducts in the lung
cancer tissue [SCC, n¼38 and AC, n¼34] and lung tissue.
Analysed
parameter
SCC n¼38 AC n¼34
Lung tissue Cancer tissue Lung tissue Cancer tissue
ph-LA [mg/ml] 20.957 2.27 11.9871.70a 18.9272.55 11.3675.97a
ph-AA [mg/ml] 46.1773.51 27.3074.98a 44.1075.01 33.8174.29a
ph-DHA [mg/
ml]
11.7271.70 7.0671.02a 10.0471.13 4.9970.97a,b
4-HNE
[nmoles/ml]
3.4671.31 9.6372.60a 3.4271.65 8.0872.87a
MDA [nmoles/
ml]
17.2472.53 70.1079.73a 19.7173.24 115.52713.65a,b
4-ONE
[nmoles/ml]
0.2370.04 0.5270.30 0.3070.08 0.5970.56
4-HNE – pro-
tein adducts
[pmoles/mg
protein]
50.0779.81 73.0278.31a 59.8773.65 103.4978.79a,b
a Statistically signiﬁcant differences vs. control group, po0.05.
b Statistically signiﬁcant differences vs. SCC group, po0.05.
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The antioxidant defence of non-small cell lung cancers is also
dependent on the activity of the Nrf2/ARE pathway (Fig. 1). SCC
and AC were both characterised by a 2-fold increase in the ex-
pression levels of the transcription factors Nrf1 and Nrf2, and their
target HO-1. Furthermore, a 3- and 6-fold decrease in the level of
the Nrf2 inhibitor Bach1 was observed in SCC and AC, respectively,
compared with control tissues. An increase in the expression levels
of proteins that activate Nrf2 - p21 and p62 was observed: the
expression of p21 increased by 25% in SCC and 90% in AC, while
the expression of p62 was enhanced by 50% and 100% in SCC and
AC, respectively. Moreover, a 2-fold increase in the level of phos-
phorylated ERK1/2 was observed in AC compared with SCC.
4.3. DNA modiﬁcations
Changes in the antioxidant defence of NSCLC were accom-
panied by an increase in the levels of DNA damage markers, such
as 8-OHdG, which increased by 2.3- and 4-fold in SCC and AC,
respectively (Table 2). The level of DNA methylation in the tested
cancer tissues was also higher by 1.4- and 2.4-fold in SCC and AC,
respectively, compared with control tissues (Table 2).
4.4. PUFAs and lipid peroxidation products
Development of NSCLC leads to disturbances in the membrane
phospholipid structure observed as changes in the levels of
phospholipid fatty acids and lipid peroxidation products (Table 3).
Our results show the stronger decrease in docosahexaenoic acid
levels in AC (up to 50%) than in SCC (to 60%), while the decrease in
both arachidonic and linoleic acid levels was at the same level
(approximately 60%) in both cancer subtypes. In both types of
cancer an increase in the levels of 4-HNE and MDA was observed.Fig. 1. The expression of the transcription factors [Nrf1 and Nrf2], their activators and in
n¼38 and AC, n¼34] and lung tissues. a – statistically signiﬁcant differences vs. controThe level of MDA was nearly 4-fold higher in SCC than in control
tissues, while in AC the levels were 6-fold higher compared with
control tissues; similarly, the levels of 4-HNE were 2.7- and 2.3-
fold higher in SCC and AC, respectively (Table 3). The increase in
the level of 4-HNE-protein adducts was higher in AC than in SCC
(increase of approximately 46% and 83% for SCC and AC, respec-
tively) (Table 3). Immunohistochemical analysis revealed that both
SCC and AC tissues had abundant 4-HNE-protein adducts present
in necrotic tissues, while strong difference was noticed between
stromal and cancer cells (Fig. 2): stromal cells were mostly positive
for the 4-HNE-protein adducts, while only some of malignant cells
exhibited prominent presence of the 4-HNE-protein adducts.
4.5. Endocannabinoid system
Cancer development leads to changes in the endocannabinoid
system. The strong difference between the tested cancer subtypeshibitors, and the inﬂammation factor NFκB as the ratio of lung cancer tissues [SCC,
l group, po0.05; b – statistically signiﬁcant differences vs. SCC group, po0.05.
Fig. 2. Immunohistochemical detection of the 4-HNE-protein adducts in SCC and AC tissues. Immunohistochemistry for 4-HNE-His presence detection by speciﬁc mono-
clonal antibodies was visualised by brown reaction of DAB (3,3′-diaminobenzidine), with the negative counterstaining with hematoxylin giving blue coloured reaction. In
malignant AC cells (upper left picture, 400 ) and SCC cells (lower left picture, 400 ) abundant presence of 4-HNE-modiﬁed proteins was observed in some cells (brown
colour, indicated by arrow), while the other cells appeared to be free of the proteins modiﬁed by the aldehyde (blue colour). Stromal cells were mostly positive for the
4-HNE-protein adducts (upper right picture, 400 ), although the nuclei of these cells did not show any presence of the 4-HNE-His adducts, as was also observed for
malignant cells. The most abundant 4-HNE-His adducts were found in necrotic regions of the cancer (lower right picture, 100 ). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article)
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level, where 1.8- and 2.3-fold increases in SCC and 1.44- and 2.3-
fold decreases in AC samples were observed (for AEA and 2-AG,
respectively) (Fig. 3). At the same time, a signiﬁcant increase in the
activity of the enzymes responsible for the degradation of en-
docannabinoids in both cancer subtypes was observed (Fig. 3).
Approximately 30% and 22% increases in FAAH activity and 47-
and 1.5-fold increases in MAGL activity were found in SCC and AC,
respectively. Moreover, the decrease in the levels of en-
docannabinoids in AC was also accompanied by an increase in the
expression of their receptors CB1/2 (approximately 50% for CB1
and 20% for CB2), which was not found in SCC. However, in both
SCC and AC, a signiﬁcant increase in the expression of other en-
docannabinoid receptors – TRV1 (33% for SCC and 56% for AC) and
GPR55 (47% for SCC and 92% for AC) was observed (Fig. 4).
4.6. Inﬂammation process
The expression level of the inﬂammation factor NFκB also
strongly shows the difference between the tested cancer subtypes
(Fig. 1). A 4-fold increase in the level of NFκB was found in SCC
compared with the controls, while no signiﬁcant changes were
found in AC.
5. Discussion
Lung tissue is continuously in contact with higher oxygenpressure than other tissues and, due to its large surface area, ex-
hibits particular susceptibility to ROS [38]. Moreover, the lung is a
major target of air pollutants, several of which are, or are meta-
bolised to, electrophiles leading to malignant transformation [2].
Therefore, lung cancer tissue is characterised by elevated oxidative
stress [39], particularly in situations when antioxidant defence
mechanisms are inefﬁcient. Although some studies have shown
increased antioxidant activities in blood cells from patients with
lung cancer [40], others have reported reduced antioxidant activ-
ities in lung tumour tissues [41,42]. Impairment of the antioxidant
defence leads to the damaging effects of electrophiles that seek
areas of high electron density, such as the purine and pyrimidine
bases of DNA resulting in 8-OHdG generation as well as direct
modiﬁcations of DNA by carcinogens with elevated levels of me-
thylated guanine as shown in this paper. Our results indicate that
the extent of modiﬁcations was higher in AC, which represents the
more aggressive form of lung cancer.
In human lung cancer cells, the higher level of DNA modiﬁca-
tions were associated with lower GSH-Px activity and reduced
gene expression of GSH-Px in normal bronchial epithelial cells,
which has been implicated as a risk factor for the development of
lung cancer in cigarette-smokers [43,44]. Our results indicate that
in the development of lung AC, more than in lung SCC, the levels of
both peroxides, including lipid peroxide degradation enzymes
GSH-Px and CAT, are diminished. Moreover, the levels of reduced
glutathione, a co-substrate of GSH-Px, are also decreased in lung
cancer tissue, which promotes a decrease in the degradation of
Fig. 3. The level of the endocannabinoids [AEA and 2-AG] and the activity of the enzymes responsible for endocannabinoids degradation [FAAH and MAGL] in the lung
cancer tissue [SCC, n¼38 and AC, n¼34] and lung tissue. a – statistically signiﬁcant differences vs. control group, po0.05; b – statistically signiﬁcant differences vs. SCC
group, po0.05.
Fig. 4. The expression of the endocannabinoids receptors [CB1, CB2, VR1, and
GPR55] as the ratio of lung cancer tissues [SCC, n¼38 and AC, n¼34] and lung
tissues. a – statistically signiﬁcant differences vs. control group, po0.05; b – sta-
tistically signiﬁcant differences vs. SCC group, po0.05.
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enhanced level of hydrogen peroxide in human lung squamous cell
carcinoma [45], as well as modiﬁcations of biomembrane phos-
pholipids in AC and SCC tissues leading to enhanced electrophilic
lipid peroxidation products such as MDA, 4-HNE and 4-ONE, as
observed in our study.
Cellular antioxidant defence mechanism is also connected with
the transcription factor Nrf2 as well as its activators and inhibitors
[46]. Nrf2 activates cellular rescue pathways against oxidative in-
jury, inﬂammation, apoptosis, and carcinogenesis through tran-
scriptional induction of a broad spectrum of genes involved in
xenobiotic detoxiﬁcation and antioxidant protection [4]. Moreover,
it has been demonstrated that Nrf2 promotes the survival not only
of normal cells but also cancer cells [47]. Therefore, prolonged
activation of Nrf2 favours the progression of several types ofcancer, including lung cancer [48] and the prognosis of such pa-
tients is poor, partly due to the ability of Nrf2 to enhance cell
proliferation, chemoresistance and radioresistance [49,50]. Ele-
vated levels of Nrf2 promote generation of antioxidants such as
GSH, and maintain the redox balance as well as the transcription
of several genes involved in the proliferation of cancer cells [51]. It
was revealed that glutathione is a critical antioxidant participating
in cell proliferation and that its level is elevated in A549 lung
cancer cells [51]. However, our results have shown the diminished
levels of GSH in both subtypes of cancer - AC and SCC, which in-
dicates the lower proliferation in lung cancer tissues. Activity of
Nrf2 is primarily regulated by Keap1, which anchors it within the
cytoplasm, targeting it for ubiquitination and proteasomal de-
gradation, thus repressing its ability to induce cytoprotective
genes [5]. The degradable complex consists of Nrf2, Keap1 and
Cul3, and somatic mutations in Keap1 and Nrf2 genes, which often
lead to disturbances in the formation of these complexes, were
shown in different cancers including lung SCC [51,52]. Moreover,
epigenetic modiﬁcations in Keap1 have also been shown to pro-
mote the accumulation of free Nrf2 in NSCLC tissue [53].
An examination of NSCLC cell lines showed that different
subtypes of lung cancer are characterised by varying degrees of
Nrf2 activation and higher activation is associated with higher
resistance to anticancer drugs as in the case of A549 cells [54]. This
study shows that this dependence occurs not only in the case of
cell lines but also in human tissues, where Nrf2 activation is
stronger in SCC than in AC. Moreover, no signiﬁcant changes in
Keap1 expression were observed in either of the examined cancer
subtypes. Therefore, high Nrf2 activity can be explained by Keap1
gene mutations leading to non-conservative amino acid substitu-
tions and nonsense mutations in 50% of the sequenced NSCLC cell
lines [55]. In the present study, we also show that p21 – a cytosolic
Nrf2 activator, is expressed at higher levels in AC. Transcription of
the p21 gene is induced by DNA damage as a consequence of the
accumulation of p53, and mediates p53-induced growth arrest to
A. Gęgotek et al. / Redox Biology 9 (2016) 210–219 217avoid the replication and subsequent propagation of potentially
hazardous mutations [56]. Other studies have shown that p21 is
also induced through a p53-independent mechanism in response
to oxidative stress [57]. Furthermore, the accumulation of p53 is
strongly connected with DNA modiﬁcations and even mutations
[58]. Moreover, it was indicated that in different subtypes of
cancers including lung cancers, the promoter region of the Keap1
gene is hypermethylated [53], which is in agreement with our
results showing enhanced levels of MetG in lung cancer tissues.
Moreover, these ﬁndings show that the expression level of another
Nrf2 activator, p62, is also enhanced in lung AC tissues and to a
lower extent in SCC tissues. It was revealed earlier that this acti-
vator may directly interact with Keap1 and sequestrate Keap1 into
phagosomes [59]. In the mouse model of Ras-induced lung ade-
nocarcinoma, the overexpression of p62 resulted in the activation
of NFκB [60]. In this study, enhanced levels of NFκB were observed
only in SCC tumours.
Keap1, as a cysteine-rich protein, is highly susceptible to in-
teractions with electrophilic compounds including lipid perox-
idation products such as reactive aldehydes [61]. The levels of
4-HNE, 4-ONE and MDA are signiﬁcantly enhanced in lung cancer
tissues. Following cysteine modiﬁcations, conformational changes
within the Keap1 homodimer cause the dissociation of Nrf2 and its
translocation to the nucleus and its transcriptional activity, leading
to enhanced expression of OH-1, as observed in this paper. It was
shown that the release of Nrf2 from the complex with Keap1 en-
sures a higher survival rate in cancer cells, especially under stress
conditions [62]. In particular, 4-HNE interferes with the expression
of many proteins connected with this transcription factor, espe-
cially the Nrf2 inhibitor Bach1 [63].
The observed increase in 4-HNE is associated with a decreased
level of AA and LA, which are the major sources of 4-HNE gener-
ated during lipid peroxidation, suggesting the metabolic pre-
ference toward lipid peroxidation of these PUFAs as has been ob-
served before in chronic obstructive pulmonary disease [64].
However, such a correlation is observed in this study for the ﬁrst
time in lung cancer tissue samples. Some of the above aldehydes
may diffuse to longer distances than ROS and act as secondary
messengers of free radicals that can propagate oxidative damage,
in particular if bound to proteins, which is the usual feature of
HNE. It was implied that aldehydes as lipid peroxidation products
only elicit damage, yet their impact could be more varied and
depend on concentration and the protein targets involved [65].
The reactive aldehydes possess an aldehydic functional group and/
or an α,β- unsaturated bond which allows them to react by both
Schiff's base formation and Michael addition, respectively. Michael
addition occurs by reaction of the electrophile with the nucleo-
philic cysteine, lysine and histidine residues of protein to form
stable covalent adducts [66]. Exposure of biological systems to
these electrophiles can modify a subset of proteins, generating a
variety of intra- and intermolecular covalent adducts relevant for
major cellular metabolic and growth regulating processes.
Therefore, it should be stressed that the increase in the 4-HNE-
His protein adducts in lung cancer tissues that is observed for the
ﬁrst time in this study is, in particular, associated with the ma-
jority of stromal cells and with some cancer cells. Similar differ-
ential expression of proteins and reactive aldehydes was pre-
viously noticed in exposure to acrolein in human prostate carci-
noma [67], where it seems to be important for the spread of cancer
and its recurrence. On the other hand, production of 4-HNE-His
adducts by non-malignant cells of the cancer tissue could be a
relevant mechanism of tumour growth control, not only because it
is well known that HNE can act as a growth regulating factor of
cancer and of non-malignant cells in speciﬁc relation to their an-
tioxidant capacities [68], but also because it was recently found
that it can speciﬁcally suppress membrane-associated catalase inthe cancer cells, thus inducing both apoptosis and necrosis of
malignant cells [69,70]. Our ﬁndings of the abundance of 4-HNE-
His adducts in necrotic lung cancer specimens favour these
options.
Moreover, aldehydic-protein adducts, denoted also as advanced
lipoxidation-end products (ALE), are potential targets for the cel-
lular and humoral immune response. Bound to proteins, these
aldehydes induce immune responses by breaking the tolerance for
cellular proteins. It has been shown that the modiﬁcation of
physiological proteins by lipid peroxidation products indeed re-
sults in the autoimmune reaction to their ALEs [71]. Although the
production of autoantibodies against cancer antigens is not con-
sidered to be a very effective defence against cancer, the cellular
reaction mediated by macrophages, lymphocytes, and granulo-
cytes could be an important defence mechanism, which will be
associated with the production of reactive aldehydes [72,73]. In
addition to histidine and lysine, another target for reactive alde-
hydes are cysteine residues in proteins but also in GSH - an
abundant low molecular mass thiol free radical scavenger [74] and
that the GSH level was found to decrease in parallel with increased
level of aldehydes in lung cancers. The pathophysiological con-
sequences of such chemical reactivity of these electrophiles are
prominent [75] because it is well recognised that the thiol groups
often act as redox switches, controlling cell signalling and meta-
bolism [76]. It should be noted that the above mentioned alde-
hydes may induce synovial intrinsic inﬂammation by activating
NFκB pathways what may lead to cell apoptosis [77] and that the
expression of NFκB was enhanced in lung cancer tissues in this
study. Because NFκB transcribes various structural proteins,
growth factors, pro-inﬂammatory cytokines and apoptotic pro-
teins, it is certain that lipid peroxidation products are involved in
the development of cancer. Moreover, the interaction with protein
kinases such as SRC and PLC could change cellular calcium sig-
nalling leading to the activation of the caspases involved in cell
death [78]. Therefore, both relatively moderate aldehydic mod-
iﬁcations of some major proteins as well as abundant accumula-
tion of non-speciﬁc aldehyde-protein adducts may be an under-
lying factor in the development of many disorders, in particular
cancer [79]. This conclusion can also be supported by the en-
hanced levels of other lipid peroxidation mediators, such as MDA,
of which increased levels have so far only been examined in the
plasma of NSCLC patients [80].
ROS/RNS and inﬂammatory mediators are implicated in the
functioning of the endocannabinoid system by changing the gen-
eration and degradation of AEA and 2-AG as well as the activation
of cannabinoid receptors (CB1, CB2, TRPV1, GPR55) [81]. It was
shown that the endocannabinoids exert potential anti-tumour
effects in various cancer cells [82], but the endocannabinoid sys-
tem may be dysregulated in a number of cancers [83]. En-
docannabinoids modulate ERK and ROS pathways leading to
apoptosis in normal and cancer cells [84]. The results of this study
showed that the altered levels of anandamide and 2-arachido-
noylglycerol are dependent on the subtype of lung cancer, with
increase in SCC and decrease in AC tissues being observed. Pre-
vious studies showed that treatment of NSCLC cell lines with AEA
or AEA degradation inhibitor [FAAH inhibitor] signiﬁcantly de-
creased the growth of tumour cells [85] and increased FAAH ex-
pression was indicated only in prostate adenocarcinoma [86].
Therefore, the increase observed in this study in the levels of en-
docannabinoids in SCC indicates that the growth of this cancer
should be diminished. Endocannabinoids are ligands of cannabi-
noid receptors, CB1, CB2, TRV1 and GPR55, among which expres-
sion of CB1/2 is decreased in SCC. This indicates that anandamide
activity is involved in independent mechanisms, e.g., via COX-2
metabolism or by TRV1 or GPR55 receptor activation [84]. How-
ever, the lung AC was characterised by higher expression of all
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levels of endocannabinoids along with higher expression of re-
ceptors are associated with the increased viability of cancer cells
[87]. Such a situation was observed only in AC, which is known to
be more aggressive than SCC. An increase in the levels of en-
docannabinoids in SCC leads to death. Data from the literature
conﬁrm that endocannabinoids control the fundamental processes
of cell homoeostasis and neoplastic transformation [86], which
agree with our results. Moreover, it was shown that the majority of
NSCLCs overexpress EGFR, which has been correlated with a poor
prognosis and resistance to chemotherapy and that CB1 or CB2
activation attenuated EGF-induced morphological changes, such as
cell elongation and generation of protrusions leading to the
rounding and reduced motility of NSCLC cells [88]. Furthermore,
signalling studies indicated that CB1 and CB2 may also act by
phosphorylation of ERK1/2, JNK1/2 and AKT, and lead to Nrf2 ac-
tivation. Moreover, endocannabinoid receptors may differentially
regulate the generation of ROS. It was shown that activation of CB1
enhances oxidative stress, whereas CB2 and TRPV1 activation
leads to suppression of oxidative stress [88]. Therefore, small
molecular weight synthetic cannabinoids inhibit growth, migra-
tion and invasion of NSCLC cells in vitro as well as in vivo in a
mouse model [89].
Finally, we conclude that lipid metabolism is not altered in the
same way in SCC and AC. Namely, lipid peroxidation appears to be
more involved in AC development, while endocannabinoids par-
ticipate more in SCC growth and development. Therefore, under-
standing the relation between the various lipid mediators and
antioxidants in different lung cancer subtypes may give the op-
portunities for further research on the targeted anticancer therapy.Conﬂict of interest
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